uridine triacetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| uridine derivatives used as antiviral agents and as antineoplastics | 5029 | 4105-38-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Uridine triacetate is an acetylated form of uridine. Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the systemic circulation of patients with hereditary orotic aciduria who cannot synthesize adequate quantities of uridine due to a genetic defect in uridine nucleotide synthesis.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 4, 2015 | FDA | WELLSTAT THERAPEUTICS CORP |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Complication associated with device | 72.06 | 57.08 | 13 | 79 | 17483 | 79726813 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AX13 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Various alimentary tract and metabolism products |
| FDA Chemical/Ingredient | N0000007587 | Pyrimidines |
| FDA Chemical/Ingredient | N0000175452 | Analogs/Derivatives |
| FDA EPC | N0000191809 | Pyrimidine Analog |
| CHEBI has role | CHEBI:49103 | drug metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
| CHEBI has role | CHEBI:78675 | fundamental metabolites |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| CHEBI has role | CHEBI:63726 | neuroprotective agents |
| CHEBI has role | CHEBI:71031 | orphan drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hereditary orotic aciduria | indication | 16242007 | |
| Antimetabolite overdose | indication | 295696001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.68 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 10GM/PACKET | VISTOGARD | BTG INTL | N208159 | Dec. 11, 2015 | RX | GRANULE | ORAL | 7776838 | Aug. 17, 2027 | EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 2WP61F175M | UNII |
| 4035398 | VANDF |
| 4035399 | VANDF |
| C0281351 | UMLSCUI |
| CHEBI:90914 | CHEBI |
| CHEBI:16704 | CHEBI |
| URI | PDB_CHEM_ID |
| CHEMBL2107381 | ChEMBL_ID |
| 20058 | PUBCHEM_CID |
| DB09144 | DRUGBANK_ID |
| 9204 | INN_ID |
| C000609666 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB02745 | DRUGBANK_ID |
| 11017 | RXNORM |
| 237553 | MMSL |
| 238118 | MMSL |
| 31371 | MMSL |
| d05935 | MMSL |
| 005776 | NDDF |
| 016442 | NDDF |
| 57763003 | SNOMEDCT_US |
| 715619008 | SNOMEDCT_US |
| C0041984 | UMLSCUI |
| CHEMBL100259 | ChEMBL_ID |
| 58-96-8 | SECONDARY_CAS_RN |
| 6029 | PUBCHEM_CID |
| D014529 | MESH_DESCRIPTOR_UI |
| 4566 | IUPHAR_LIGAND_ID |
| WHI7HQ7H85 | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VISTOGARD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69468-151 | GRANULE | 951 mg | ORAL | NDA | 25 sections |
| XURIDEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69468-152 | GRANULE | 951 mg | ORAL | NDA | 26 sections |
| XURIDEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69468-152 | GRANULE | 951 mg | ORAL | NDA | 26 sections |